Home > Analyse
Actualite financiere : Actualite bourse

Merck: Phase III trial in lung cancer fails

(CercleFinance.com) - Merck announces that, on the recommendation of an independent data monitoring committee, it has stopped the KeyVibe-008 phase III trial for the first-line treatment of patients with extensive-stage small-cell lung cancer.


This trial evaluated the investigational fixed-dose combination of vibostolimab and pembrolizumab (Keytruda), in combination with chemotherapy, versus atezolizumab in combination with chemotherapy.

Data showed that the primary endpoint of overall survival met pre-specified futility criteria, as well as higher rates of adverse events, including immune-related events, than in the control arm.

Merck therefore warns that patients in the study should discontinue fixed-dose vibostolimab and pembrolizumab and be offered the option of atezolizumab. Results will be shared with the scientific community.


Copyright (c) 2024 CercleFinance.com. All rights reserved.